Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety

Umberto Vitolo, Lorenzo Falchi, Sylvia Snauwaert, Fritz Offner, Marcel Nijland, Per-Ola Andersson, Poliana Patah, Isil Altintas, Jennifer Marek, Malene Risum, Yi Hao, Joshua Brody

Blood (2025) 146 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2025-5357

Published: 2025

Journal Articles

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

Lori Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Christensen, Alexander Fosså, Marjolein Van Der Poel, Joost Vermaat, Fritz Offner, David Belada, Jian Mei, Isil Altintas, Malene Risum, Aidan Reilly, Liwei Wang, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 465.

https://doi.org/10.1182/blood-2025-465

Published: 2025

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023